Therapeutic bacterial composition
AssigneeMicrobiotica Limited
InventorsGhaith Bakdash, Simon Harris, Dominika Klisko, Trevor Lawley, Seánín McCluskey, Thomas Mitchell, Anne Neville, Amy Popple, Oliver Rimington, Matthew Robinson, Michael Romanos, Adam Wilkinson
Life of this patent
Estimating the term…
Abstract
The disclosure relates to therapeutic compositions comprising isolated bacteria useful in the treatment of ulcerative colitis or Crohn's disease. Related methods and uses are also disclosed.
Claims14
A composition comprising isolated bacteria from at least four bacterial species and one or more stabilisers and/or cryoprotectants, wherein the bacteria from the first species comprise a 16S rDNA sequence having at least 98.7% sequence identity with a nucleic acid sequence according to SEQ ID NO:
- 1, the bacteria from the second species comprise a 16S rDNA sequence having at least 98.7% sequence identity with a nucleic acid sequence according to SEQ ID NO:
- 2, the bacteria from the third species comprise a 16S rDNA sequence having at least 98.7% sequence identity with a nucleic acid sequence according to SEQ ID NO:3 and the bacteria from the fourth species comprise a 16S rDNA sequence having at least 98.7% sequence identity with a nucleic acid sequence according to SEQ ID NO:
- 5.
A method for treating ulcerative colitis or Crohn's disease comprising administering a therapeutically effective amount of a composition comprising isolated bacteria from at least four bacterial species wherein the bacteria from the first species comprise a 16S rDNA sequence having at least 98.7% sequence identity with a nucleic acid sequence according to SEQ ID NO:
- 1, the bacteria from the second species comprise a 16S rDNA sequence having at least 98.7% sequence identity with a nucleic acid sequence according to SEQ ID NO:
- 2, the bacteria from the third species comprise a 16S rDNA sequence having at least 98.7% sequence identity with a nucleic acid sequence according to SEQ ID NO:3 and the bacteria from the fourth species comprise a 16S rDNA sequence having at least 98.7% sequence identity with a nucleic acid sequence according to SEQ ID NO:
- 5 to a subject, optionally wherein the composition is administered by oral administration or rectal administration, further optionally, wherein the composition or pharmaceutical composition is administered prior, concurrently or after treatment with another treatment for ulcerative colitis or Crohn's disease.
Dependencies are inferred from the claim text.